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Ekspresija ciklooksigenaze-2 kod karcinoma grliüa materice
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Goran Malenkoviü
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Abstract
Background/Aim. Cyclooxygenase (COX) or prostaglan-
din H2 synthase is the first enzyme that catalyzes the first
two steps in the biosynthesis of prostaglandins from arachi-
donic acid. The aim of the study was to determine the ex-
pression level of COX-2 in patients with cervical cancer and
compare it with that in the control group with no cervical
pathology.  Methods.  The study included 76 patients di-
vided into two groups: the control group – 30 patients
without histopathological changes and the group A – 46
patients with cervical cancer, FIGO stage IB-IIA. Histo-
pathological and immunohistochemical analyses were per-
formed in these two groups of patients. Results.  In the
control group, the expression of COX-2 was not confirmed
compared to the group A of 26 (56.52%) patients. The ex-
pression of COX-2 showed a statistically significant differ-
ence in the presence of lymphocytic stromal infiltration (p =
0.0053). The expression of COX-2 was more pronounced in
the stromal tissue without lymphocytic infiltration (80% vs
20%). Conclusion. A higher expression of COX-2 in cervi-
cal carcinoma without stromal lymphocytic infiltration sug-
gests a possible paradoxical effect of COX-2 in immuno-
suppression. Frequent COX- 2 expression in the subgroup
with poor prognostic histological parameters in the group A
indicates the importance of COX-2 expression in the carci-
nogenesis of cervical cancer.
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Apstrakt
Uvod/Cilj. Ciklooksigenaza (COX) ili prostaglandin H2 sintaza
(PGHS) prvi je enzim koji katalizuje prva dva koraka biosinteze
prostaglandina iz arahidonske kiseline. Cilj rada bio je da se is-
pita prisustvo i stepen ekspresije COX-2 u tkivu grliýa materice
ispitanica sa cervikalnim karcinomom i uporedi sa kontrolnom
grupom bez cervikalne patologije. Metode.  Istraživanjem je
obuhvaýen patohistološki materijal uzet od 76 bolesnica pode-
ljenih u dve grupe: kontrolna grupa – 30 bolesnica bez patohis-
toloških promena na grliýu materice i grupa A – 46 bolesnica sa
verifikovanim karcinomom grliýa materice, FIGO stadijum IB-
IIA. U obe grupe na patohistološkom materijalu izvršene su hi-
stološke i imunohistohemijske analize. Rezultati. U kontrolnoj
grupi nije potvrĀena ekspresija COX-2, a u grupi A jeste kod 26
(56,52%) bolesnica što je statistiÿki znaÿajna razlika u odnosu na
kontrolnu grupu. Ispitivanjem ekspresije COX-2 i patohistološ-
kih parametara, uoÿena je statistiÿki znaÿajna razlika  u odnosu
na postojanje limfocitne infiltracije (p = 0,0053). Ekspresija
COX-2 bila je izraženija u tkivu bez limfocitne stromalne infil-
tracije (80% vs 20%). Zakljuÿak. Ekspresija COX-2 bila je izra-
ženija kod karcinoma grliýa materice bez limfocitne stromalne
infiltracije što navodi na zakljuÿak o moguýem paradoksalnom
efektu COX-2 na imunosupresiju u tumorskom tkivu. Nalaz ÿe-
šýe ekspresije COX-2 u podgrupi sa lošijim prognostiÿkim pa-
tohistološkim parametrima u grupi A upuýuju na znaÿaj aktiv-
nosti ekspresije COX-2 u procesu karcinogeneze karcinoma gr-
liýa materice  i uticaja na njegovu progresiju.
Kljuÿne reÿi:
grliý materice, neoplazme; prostaglandin sintetaza;
imunohistohemija; geni, ekspresija; osetljivost i
specifiÿnost.
Introduction
According to the global scale, cervix uteri carcinoma
remains in the second place among female population of dis-
eased from the malignant neoplasia, with about 400,000
newly diagnosed cases per year with annual mortality of
about 250,000 women. Approximately 83% of cervical car-
cinoma is diagnosed in underdeveloped and developing
countries, which do not have any adequate screening pro-
grams 
1. According to the data obtained from the Cancer
Registry of the Central Serbia, cervical carcinoma is the most
frequent malignant tumor of the female reproductive organs
with the incidence rate of 26.9/100,000. The same data from
2001 show the frequency of cervical carcinoma of 9.4% inStrana 998 VOJNOSANITETSKI PREGLED Volumen 71, Broj 11
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the total number of the diseased and 5.8% in total mortality
from malignant tumors of the female population 
2. According
to the Malignant Diseases Registry of the Oncology Institute
of Vojvodina, the incidence of 26.6/100,000 was registered
in Vojvodina, for the period from 1993 to 2002 
3. Former re-
search in oncology contributed to the definition of the cyclo-
oxygenase-2 (COX-2) expression significance in tumor cell
oncogenesis. In oncogenetic expression, a more significant
role is played by COX-2, whose expression is related to
various pathophysiological conditions of inflammation or
oncogenesis 
4. Furthermore, studies show the significance of
COX-2 expression in regulation of apoptosis, disease pro-
gression, neoangiogenesis and the therapeutical response
 4–7.
Liu et al. 
8 presented COX-2 expression growth in more se-
vere cases of esophagus squamous neoplasia. Lim et al. 
9
also confirmed the increase in COX-2 expression in ade-
nomatous and metaplastic stomach lesions. Saukonen et al. 
10
presented COX-2 expression in 44% of patients with dys-
plastic changes in stomach. Also, COX-2 expression was
confirmed in other neoplastic lesions of the breast, urinary
bladder and pancreas 
7, 11, 12. Ferrandina et al. 
13 also pub-
lished the results of COX-2 expression study in precancerous
and cancerous changes of vulva. They confirmed a higher
level of COX-2 expression in more advanced stages of vulva
carcinoma (FIGO stages III/IV), with metastatic lymph
nodes and deeper stromal infiltration.
COX-2 expression was a significant factor in the in-
crease of tumor angiogenesis and the reduction of apoptosis,
which appeared as a possible, important connection within
the development of carcinogenesis and tumor growth
 14, 15.
The aim of this paper was to: test the presence and the
level of COX-2 expression in cervical tissue of the female
patients divided into two groups – the control group and the
group A (cervical carcinoma, FIGO stage I-IIA), and to
compare the COX-2 expression level in the patients diag-
nosed with the cervical carcinoma in relation to the level of
tumor differentiation, stromal invasion, tumor size, the pres-
ence of lymphovascular invasion and the existence of me-
tastases in the lymph nodes.
Methods
The study included histopathological material from 76
patients who underwent surgery with performed hysterec-
tomy with or without adnexectomy due to benign changes in
the uterus (myomas) or, with performed radical hysterectomy
on the basis of biopsy verified cervical carcinoma, FIGO
stage IB-IIA. The trial was conducted at the Clinic for Op-
erative Oncology and the Center for Pathology and Diagnos-
tic Cytology of the Oncology Institute of Vojvodina in Srem-
ska Kamenica.
Based on the definite histopathological findings, the
patients were divided into two groups: the control group
(without changes at the cervix uteri) and the group A (cervi-
cal carcinoma, FIGO IB-IIA).
The control group included histopathological material
of 30 patients who underwent total hysterectomy due to be-
nign changes in the uterus and/or ovaries.
Exclusion criteria for this group of patients were the
patients with: previous excision or ablation of the cervix
uteri: precancerous or cancerous lesions diagnosed in the
cervix uteri; verified chronic inflammation of the cervix
uteri; verified malignant disease of the genital tract; verified
malignant disease of any other localization.
The group A included histopathological material of 46
patients with verified cervical carcinoma FIGO stage IB-IIA,
who underwent radical Piver, class III surgery, with lymph-
adenectomy.
Exclusion criteria for this group were the patients: with
verified cervical carcinoma who were previously treated by
irradiation therapy or neoadjuvant cytostatic therapy; who
previously underwent an excision or ablative type of cervical
treatment; with verified malignant disease of the genital tract
of other localization; with verified malignant disease of any
other localization.
The obtained surgical material was sent to histopatho-
logical (HP) examination.
Histopathological examination enabled the definition of
the final histopathological diagnosis, determination of the
stage of the tumor disease and the analysis of the standard
histopathological prognostic parameters: histological type of
the tumor; tumor size and the depth of the stromal invasion;
grade of histological differentiation; the presence of lympho-
vascular invasion; the total number of removed lymphatic
nodes; the presence of metastases and the number of me-
tastatically changed lymphatic nodes.
Examination included all resection edges of parame-
trium and vagina, for determination of the presence or ab-
sence of the tumor.
Based upon the HE stained preparations, a representa-
tive sample from the examined material was selected for
immunohistochemical testing.
Immunohistochemical analysis of COX-2
For immunohistochemical analyse, the selected tissue
samples from the control group (hysterectomy due to my-
omatous uterus) and the group A (radical hysterectomy) were
used. The samples were fixed in formalin and blocked in
paraffin, sliced into sections of 4 micron thickness, and then
“glued” to Superfrost (Menzel-Glaser) positively electrified
glass slides, previously prepared for immunohistochemical
reactions. After deparaffinization, we started blockage of en-
dogenous peroxidase with 3% H2O2 for 5 minutes. Immu-
nohistochemical identification of the tested antigens was per-
formed by application of Streptavidin-biotin-peroxidase
technique (B-0SA), according to the standard LSAB proce-
dure (Dakocytomation-DAKO). The fragments were incu-
bated for 30 minutes at room temperature with biotinylated
anti-mouse antibody, and then incubated with streptovidin-
peroxidase complex system, in duration of 30 minutes. As a
hromogenous substrate, a 3-amino-9-ethylcarbazole (AEK,
DAKO) was applied. After each incubation the samples were
rinsed in Tris buffer solution (TBS: 0.05 M, pH 7.6). Con-
trasting was performed by hematoxylin. The tissue samples,
which, during the treatment missed the primary antibody,
were used as the negative control for antibody, while theVolumen 71, Broj 11 VOJNOSANITETSKI PREGLED Strana 999
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other phases of the immunohistochemical procedure were
applied. The analysis of immunohistochemically processed
tumor tissue samples was performed by light-microscopy, by
qualitative and semi-qualitative method, expressed as the
percentage of positive cells in relation to the total number of
cells in the representative fields.
The value of COX-2 expression was analyzed semi-
qualitatively, by determination of the percentage of the
stained tumor cells 
16: absence of expression – negative
findings; mild level of expression - < 25% of the changed
cells were positive; medium level of expression – > 25.1–
50% of the changed cells were positive; high level of expres-
sion –  50.1% of the changed cells were positive.
As internal negative control, tumor unchanged epithe-
lial cells of the cervix were used. As positive external tissue
control for COX-2 expression, a high-grade transitional cel-
lular urinary bladder carcinoma was used 
17.
During statistical analysis of data, descriptive statistics
were calculated – frequencies, percentages, mean values, and
a standard deviation.
We used graphical presentation of data and the results
with the aid of column diagrams and box-whiskers diagrams.
Comparisons were performed by the t-test, numerical-
feature-variance analysis.
For attributive features, the non-parametric, Pearson’s
Ȥ
2-test and Fisher’s exact test were used.
Statistically significant differences (p < 0.05)  were
marked by the asterisk (*), and highly significant difference
(p < 0.01) by two asterisks (**).
Statistical data analysis was performed with the aid of
the software package STATISTICA 9.0 for which, there is a
University license at the Novi Sad University. Data analysis
and presentations (tables and graphs) were prepared by the
computer technique in programs Microsoft Word, Excel and
Power Point.
Results
The study results were obtained by the analysis of
histopathological material from 76 patients and their statisti-
cal processing. The material was collected at the Gyneco-
logical Oncology Department and analyzed at the Pathology
and Cytodiagnostics Department of the Oncology Institute of
Vojvodina in Sremska Kamenica.
The mean age of the patients in the control group was
46.19 years. The youngest patient was 30 and the oldest one
67 years of age (ʉ ± SD = 46.19 ± 8.284).
The mean age of the patients in the group A was 50.13
years. The youngest patient was 31 and the oldest 66 years of
age (ʉ ± SD – 50.13 ± 10.417).
In the control group, histopathological findings showed
the normal cervix uteri without any histopathological
changes.
In the group A, in all 46 patients, a planocellular type of
carcinoma was verified in the final histopathological find-
ings. According to the FIGO classification in 34 (74%) of the
patients, the disease was staged as IB1, i.e. stage IB2 in 12
(26%) of the cases.
Beside histological type and the stage of the disease,
histopathological examination also analyzed standard prog-
nostic parameters: size of the tumor, depth of stromal inva-
sion, total number of removed lymphatic nodes, the number
of metastatically changed lymphatic nodes, degree of his-
tological differentiation, the presence of lymphovascular in-
vasion, involvement of parametrial and vaginal resection
edges, involvement of “isthmus” of uterus and the presence
of lymphocyte infiltrate. The tumor size was up to 2 cm in
47.83% of the patients. In 69.57% of the patients, the depth
of stromal invasion was greater than 10 mm, and more than
10 lymph nodes were removed in 71.74% of the patients. In
17 patients, out of 46, the presence of metastases in the
lymph nodes was diagnosed. In 11 patients, two or more
lymph nodes were positive. The degree of histological dif-
ferentiation was distributed in the following manner: G1
(17.39%), G2 (58.69%) and G3 (23.92%). Lymphovascular
infiltration was not registered in 60.87% of the patients.
“Isthmus” of uterus infiltration was verified in 23.91% of the
patients. In 56.52% of the patients, there was lymphocyte
stromal infiltration. Parametrial and vaginal infiltration of the
cuff was not confirmed in 93.48%, i.e. 91.30% of the pa-
tients (Table 1).
After histopathological analysis, the preparations were
stained immunohistocemically for testing of the COX-2 ex-
pression characteristics. Fisher’s exact test and Pearson’s Ȥ
2-
test were used for testing of the difference between the ex-
amined groups.
In the control group, there was no COX-2 expression
confirmed, while in the group A, it was verified in 26
(56.52%) patients (Figure 1).
By comparison of COX-2 expression between the ex-
amined groups, it was determined that there was a highly
statistically significant difference between the control group
and the group A (p = 0.0001) (Figure 2).
The control group did not show COX-2 expression in
the entire examined histopathological material. Further com-
parison of expression was tested within the group A.
The level of COX-2 expression was divided into: the
absence of expression or negative COX-2; mild level of ex-
pression – < 25% of the changed cells were positive; medium
level of expression – 25.1–50% of the changed cells were
positive; high level expression –  50.1% of the changed
cells were positive.
In the group A, mild, medium and high expression of
COX-2 was in 17.39%, 15.22% and 23.91% of cases of
the examined histopathological material respectively
(Figure 3).
Testing of COX-2 expression and histopathological
parameters showed a statistically significant difference in
relation to the existence of lymphocyte infiltration
(p = 0.0053). Positive COX-2 expression was greater in the
tissue of the patients without lymphocyte stromal infiltra-
tion (16/20, 80%). In the patients with lymphocyte stromal
infiltration, positive expression was verified in 10/26
(38.46%) patients. There was no statistically significant
difference confirmed regarding other histopathological pa-
rameters (p > 0.05) (Table 2).Strana 1000 VOJNOSANITETSKI PREGLED Volumen 71, Broj 11
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Table 1
Frequency of histopathological parameters in the group A (with cervical cancer)
Histopathological variables Frequency Percentage
Size of the tumor
up to 2 cm
over 2 cm
22
24
47.83
52.17
Total 46 100
Depth of stromal invasion
up to 10 mm
over 10 mm
14
32
30.43
69.57
Total 46 100
Number of lymph nodes
up to 10
more than 10
13
33
28.26
71.74
Total 46 100
Number of lymph nodes with metastases
1 positive lymph node
2 or more positive lymph nodes
6
11
35.29
64.71
Total 17 100
Degree of histological differentiation
G1 8 17.39
G2 27 58.69
G3 11 23.92
Total 46 100
Lymphovascular infiltration
Yes 18 39/13
No 28 60.87
Total 46 100
Lymphocyte stromal infiltration
Yes 26 56.52
No 20 43.48
Total 46 100
“Isthmus” infiltration
Yes 11 23.91
No 35 76.09
Total 46 100
Parametrial infiltration
Yes 3 6.52
No 43 93.48
Total 46 100
Vaginal cuff infiltration
Yes 4 8.70
No 42 91.30
Total 46 100
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Fig. 1 – Frequency of COX-2 expression per groups. Fig. 2 – Immunohistochemical identification of COX-2 in the
group A (with cervical cancer) (LSBA, ×200).
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Table 2
Comparison of COX-2 expression of lymphocyte stromal infiltration in the group A (with cervical cancer)
COX-2 expression Positive, n (%) Negative, n (%) Total, n (%) Fisher exact test p – values
Lymphocyte stromal infiltration
Yes 10 (38.46) 16 (71.54) 26 (100)
No 16 (80) 4 (20) 20 (100) 0.0053*
Total 26 (56.52) 20 (43.48) 46 (100)
In the subgroup of patients with worse histopathological
prognostic parameters, positive lymph nodes (17/46), lym-
phovascular infiltration (18/46), “isthmus” of uterus infiltra-
tion (11/46), there was a statistically significant difference in
relation to the existence of COX-2 expression (positive
COX-2 – 70.59%, 66.66%, 63.54%, and negative COX-2 –
29.41%, 33.34%, 36.36%, respectively; p < 0.05) (Figure 4).
71%
29,41%
67%
33%
63,64%
36%
0%
50%
100%
Positive lymph nodes  Lymphovascular
infiltration
“isthmus” of uterus
infiltration 
Positive COX-2 Negative COX-2
Fig. 4 – Frequency of COX-2 expression in the subgroup of
patients with worse histopathological prognostic parameters
within the group A (with cervical cancer).
In the other subgroups in the patients with the tumor
greater than 2 cm, the level of histological differentiation and
the depth of stromal invasion greater than 10 mm, there was
no statistically significant difference in relation to COX-2
expression (p > 0.05). In a subgroup of patients with para-
metrial and vaginal infiltration of the cuff, due to a small
sample (3, i.e. 4), statistical analysis was not performed.
The existence of a highly statistically significant differ-
ence in relation to the presence of lymphocyte stromal infil-
tration (p = 0.003) and the degree of COX-2 expression was
determined. In patients with a medium degree of expression,
100% of the tested samples did not have lymphocyte stromal
infiltration. Lymphocyte stromal infiltration was not present
in 54.55% of the patients with the high COX-2 expression
(over 50%) (Figure 5).
The degree of COX-2 expression in relation to the other
histopathological parameters did not show a statistically sig-
nificant difference (p > 0.05).
Discussion
Over 85% of deaths caused by cervical carcinoma are
registered in the undeveloped countries. Observing the entire
epidemiological picture, at the moment, Serbia is in the fifth
place (19.6/100,000) in Europe for cervical carcinoma inci-
dence, and in the third place for mortality (8.6/100,000) 
18.
Researching COX-2 expression as a pro-oncogene acti-
vator contributed to wider knowledge of oncogenesis, but
also imposed some new questions and goals to researchers.
COX expression was proved in many premalignant, malig-
nant and metastatic diseases regardless the tumor type and
localization 
4, 19. Studies confirmed COX-2 expression in
premalignant breast changes, adenomatous colon polyp, leu-
koplakia of buccal mucosa 
20–22. Expression was also deter-
mined in urinary bladder carcinoma, breast, colon, lung, pan-
creas, stomach, kidneys, skin carcinoma, lymphoma, sar-
coma, leukemia, brain tumor
 19, 23–30. Researching COX-2 ex-
pression, its role in carcinogenesis and as a prognostic factor,
was also presented in studies on malignant diseases of the
lower genital systems in women.
Li et al. 
31 presented expression of COX-2 in ovarian
low malignant potential tumor (borderline) (57.9%) and car-
cinoma (81.5%) in relation to benign ovarian tumors
(38.9%). They also determined a statistically significant dif-
ference between COX-2 expression and the clinical stage of
ovarian low malignant potential tumor (borderline) (FIGO
stage I/II –51.7% and stage III/IV – 90.9%). Denkert et al. 
32
analyzed COX-1 and COX-2 expression in 117 ovarian tu-
mor samples and 2 ovarian tissue samples without any
changes. COX-2 was only detectible in malignant, changed
tissue (42%). In univariate analysis, COX-2 expression was a
bad prognostic factor. The mean survival in the patients with
4
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negative COX-2 was 52 months in comparison to 30 months
in COX-2 positive. In this study, the multivariate analysis
showed that COX-2 expression is an independent bad prog-
nostic factor (relative risk, RR = 2.74, 95% CI : 1.38–5.47).
Chou et al. 
33 showed more expressed COX-2 expression in
ovarian carcinoma (which was related to endometriosis) than
in the isolated carcinoma (27.8% vs 5.6%). In endometrial
type of ovarian adenocarcinoma, a statistically significantly
greater COX-2 expression was confirmed when compared to
the isolated ovarian carcinoma (50% vs 0%; p = 0.023). Na-
sir et al. 
34 tested COX-2 expression in endometrial adeno-
carcinoma (EAK), atypical complex hyperplasia (AKH) and
endometrial hyperplasia (EH). COX-2 expression was
proved in 88% of EAK, 80% of AKH and 44% of EH. The
mean value of COX-2 immunohistochemical score for EH
i.e. EAK was 33 (SD ± 24.11) and 76 (SD ± 54.57), respec-
tively; p = 0.022.  Ferrandina et al. 
35 tested 69 samples of
primary endometrial carcinoma. The expression of COX-2
was confirmed in 39.1% of cases. The COX-2 positivity was
more pronounced (60.8%) in case of endometrial expansion
to the cervix and outside the uterus, in contrast to carcinoma
limited to the body of uterus (28.3%; p = 0.017). The authors
showed the increase of COX-2 expression with the increase
of the histological grade level (G1 – 13.6%, G2 – 41.7%, G3
– 60.9%; p = 0.0049). A statistically significant difference in
expression was determined in relation to the depth of the
myometrial invasion (<  50–15.6%, >  50–66.7%). Nofech-
Mozes et al. 
36 tested the immunohistochemical score of
COX-2 expression in a group with inflammatory changes in
the vulva (1.6), VIN I and II (1.4), VIN III and carcinoma in
situ (0.7) and invasive vulvar carcinoma (1.2) with the exis-
tence of a statistically significant difference, but not the rela-
tion with the level of dysplasia or age.
In our study, we tested COX-2 expression in cervix
uteri tissue without pathological changes and with carci-
nomatous changes. The expression of COX-2 was not con-
firmed in the control group, in opposition to the group A
(56.52%). A statistically significant difference was deter-
mined in relation to positive expression between the control
group and the group A. The control group did not show
COX-2 expression in the entire examined material and thus,
it was confirmed as an internal negative control for normal
cervix uteri tissue. The specificity of COX-2 protein expres-
sion is in its significant role in an inflammatory process, and
an important precursor of premalignant and malignant
changes in the cervix uteri is a long-term inflammatory proc-
ess
 37.  A significant role in this mechanism has a persistent
viral infection with human papillomaviruses of high onco-
genic potential. Subbaramaiah et al. 
38 presented a complex
mechanism of COX-2 expression activation, activated by on-
coproteins HPV 16 E6 and E7 at line cells of normal cervix
and carcinoma. The activation of COX-2, induced by HPV
16 E6 was done through a complex mechanism by activation
of epidermal growth factor receptors (EGFR), Ras, mitogen-
activated protein kinase (MAPK) and activator protein-1
(AP-1). The expression of E6 and E7 leads to corepressor in-
hibition (NCoR). A potential mutual activity also coactivates
the corepressor with HPV16 E6 and E7 oncoproteins in a
complex mechanism of mutual activation and degradation,
inducing expression of COX-2. Farley et al. 
39 published a
paper on the expression of COX-2 in precancerous cervical
changes. The study included 62 cervical samples obtained by
the LEEP technique (loop electrosurgical excision proce-
dure), which included 18 CIN 1, 19 CIN 2 and 25 CIN 3
changes. The positive expression of COX-2 was marked if
there was positivity in more than 50% of cells in the exam-
ined sample. In CIN 1 changes, the expression of COX-2
was observed in 50%, CIN 2 in 42% and CIN 3 in 68% of
the patients. The average intensity of expression was grow-
ing with the level of dysplasia (CIN 1 – 1.6; CIN 2 – 1.8;
CIN 3 – 2.1). The authors pointed out COX-2 expression,
which might play a role in carcinogenesis of cervical carci-
noma. Dai et al. 
16 presented 45% of patients with CIN
changes, who were positive to COX-2 expression. Similar
results were confirmed by Kim et al. 
40 with the expression
of COX-2 in 24% of the patients with CIN 3 changes in the
cervix uteri, in 37.9% in microinvasive cervical carcinoma
and in 51.6 % of patients with invasive carcinoma. In their
study, Dursun et al. 
41 tested the expression of COX-2 in CIN
changes of the cervix uteri and planocellular carcinoma and
made comparisons with clinicopathological factors. The
study included 25 patients with CIN 3 changes and 67 pa-
tients with cervical carcinoma. Positive expression of COX-2
was confirmed in 24% of patients in the group with CIN 3
changes, while it was confirmed in 55.2% of patients with
carcinoma. A correlation of COX-2 expression and the pres-
ence of lymphovascular invasion (LVI) showed a statistically
significant difference (positive LVI – 61.9% of the patients
with positive COX-2; negative LVI – 33.3%, p = 0.02).
Furthermore, statistically significant difference was shown in
relation to the size of the tumor (up to 4 cm – 39% of pa-
tients with positive COX-2 and over 4 cm – 65.9%;
p  =  0.028). A statistically significant difference related to
parametrial infiltration, lymph node status or recurrence dis-
ease and survival was not confirmed. In multivariate analy-
sis, lymphovascular invasion was the only factor connected
to the expression of COX-2, unlike the size of the tumor 
41.
In Khunamornpong et al. 
42 study COX-2 expression was
significantly associated with lymph node metastasis but
lacked a significant correlation with tumour stage, size, his-
tologic grade, deep stromal invasion, lymphovascular space
invasion (LVSI), and parametrial involvement. COX-2 ex-
pression was not associated with lymph node metastasis in
the absence of parametrial involvement or LVSI. In the cases
with LVSI, COX-2 expression was significantly associated
with lymph node metastasis.
Comparison of risk factors and the stage of the disease
in relation to COX-2 expression and its level within the
group A did not prove a statistically significant difference.
Luo et al. 
43 tested COX-2 expression in cervical carcinoma
and its clinical significance. Seventy-two cervical samples
with invasive carcinoma and 16 cervical samples without
tumor were examined. Within the group with the invasive
carcinoma, COX-2 expression was present in 88.9% of cases
and in the group without the tumor in 12.5 %. COX-2 ex-
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and stromal invasion. A similar study was conducted by
Manchana et al.
44 where they tested the prevalence of COX-
2 and compared it with the clinicopathological factors. The
study included 89 samples of cervical carcinoma, which
were obtained after radical hysterectomy. COX-2 expression
was confirmed in 49.4% of samples, while the greatest num-
ber was related to adenocarcinoma (86.7%) when compared
to planocellular type (40.6%). A statistically significant dif-
ference was confirmed by comparison of COX-2 expression,
the presence of lymph nodes metastases (100% vs 46.4%)
and the presence of parametrial infiltration (80% vs 47.6%).
A significant difference was not confirmed in relation to age,
size of the tumor, depth of stromal invasion and lymphovas-
cular invasion. The correlation between COX-2 expression
and a five-year-long survival was not confirmed (positive
COX-2 – 81%, negative COX-2 – 98%). Although the cor-
relation of COX-2 expression, histological type and lymph
node status was not confirmed, the authors concluded that
COX-2 expression cannot be pronounced as a significant
prognostic factor with absolute certainty.
A meta-analysis of Huang et al. 
45 indicated that COX-2
overexpression might be an unfavorable prognostic factor
and chemoradiation resistance predictive factor for cervical
cancer.
An association between COX-2 expression and para-
aortic lymph node recurrence has been reported in advanced
stage patients treated with radiation therapy 
46. Also, some
reports documented a better pathological response to che-
motherapy in patients with negative COX-2 protein 
47. Still
further studies need to correlate the expression of COX-2
with reccurence cervical cancer and the correlation of sur-
vival rate with COX-2 expression.
In the group A, with planocellular histologic type of the
tumor and FIGO stage of the disease IB, COX-2 expression
was confirmed in 56.5% of cases, similar to previously pub-
lished results. A correlation of histopathological parameters
and COX-2 expression, unlike the presented results of the
other authors, did not show a statistically significant differ-
ence, but it should be noted that their data also differed.
This difference in the results is related to clinicopa-
thological factors and it is possible that it lies in heterogene-
ity of the samples (number, stage, histological type), meth-
ods of testing of COX-2 expression (immunohistocemically,
titer in blood, COX-2mRNA). The results of more frequent
positive expression of COX-2 in the subgroup with worse
prognostic histopathological parameters refer to the signifi-
cance of the activity of these factors in carcinogenesis of
cervix uteri carcinoma.
Observing COX-2 expression in our study, a statisti-
cally significant difference was determined in relation to
lymphocyte stromal infiltration (p = 0.0053). In the available
published papers, the presence of lymphocyte infiltration was
not observed as a clinicopathological factor. Immunosup-
pression is an important factor in regulation of the activity
and aggressiveness of a malignant disease. This represents a
controversy in positive expression of COX-2 and its role in
prostaglandin stimulation in tumor tissue, which leads to
suppressing of immune system cells, thus creating an immu-
nosuppressive area with the reduced immunological defense
mechanism against the tumor tissue. Fourteen years ago,
Staveley-O’Carroll et al. 
48 described the induction anergy of
T-lymphocytes in early oncogenesis. T-cell and dendritic cell
defect, caused by the production of prostaglandin, which are
stimulated by COX-2 expression, can play a significant role
in tumor evasion of the immune system 
4. This can be indi-
rectly observed in relation to the presence or the absence of
lymphocyte infiltration in and around tumor tissue in relation
to COX-2 expression.
Conclusion
There was the outstandingly significant COX-2 expres-
sion in the group with cervical carcinoma when compared to
the control group. The positive correlation of COX-2 expres-
sion in the group with carcinoma shows a possible correlation
with carcinogenesis of cervix uteri carcinoma. A statistically
significant positive correlation between COX-2 expression and
certain individual histopathological parameters in the group A
was not proved, which was the basis for discarding the possi-
bility of implementation of COX-2 as a marker for prognostic
purposes in patients with neoplastic cervical lesions. COX-2
expression was more pronounced in cervical carcinoma with-
out lymphocyte stromal infiltration, which led to the conclu-
sion of a possible paradoxical effect of COX-2 to immunosup-
pression in tumor tissue. This conclusion requires some addi-
tional research. More frequent COX-2 expression in the sub-
group with worse prognostic histopathological parameters in
the group A, points to the significance of COX-2 expression
activity in the process of cervix uteri carcinoma carcinogenesis
and the impact to its progression.
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